Lanqi Biomedical’s LXP108 Phase I clinical trial showed robust safety performance and the development process continues to move forward
2026/05/05 16:25:53 Economic Daily Reporter Ren Junxiang/Taipei Live Report Longchi Biomedical* (6876) stated on the 5th that the company’s independently developed multi-target kinase inhibitor candidate new drug LXP108 (LXP1788 Injection), the first phase of dose escalation clinical trials for advanced solid tumors is progressing smoothly, and the fourth dose group of 0.72 has been completed. mg/kg, once weekly dosing (QW) safety review, and successfully advanced to the next dose group.
Langzi Biomedicine said that the current treatment of advanced solid tumors still faces multiple challenges, including high tumor heterogeneity, resistance to single-target drugs, limited back-line treatment options, and the lack of effective treatment options for some patients after existing treatments. LXP108 is designed with multi-target kinase inhibition as the core. It hopes to supplement the limitations of existing single-target treatments in tumor escape and drug resistance control by simultaneously regulating multiple message transmission pathways related to tumor growth, metastasis and drug resistance. This differentiated design gives LXP108 the potential to be applied to a variety of advanced solid tumors and is expected to provide new solutions to highly unmet clinical treatment needs.
Up to now, LXP108 has completed evaluation in dose groups of 0.09, 0.18, 0.36 and 0.72 mg/kg, and no dose-limiting toxicity (DLT), serious adverse event (SAE) or suspected unexpected serious adverse drug reaction (SUSAR) has been observed. Among them, the fourth dose group of 0.72 mg/kg has entered the dose range with clinical observation significance. It still maintains good safety and tolerability at this stage, providing positive support for the subsequent advancement of higher dose groups and the evaluation of preliminary efficacy signals.
In addition, in the 0.72 mg/kg dose group, one neuroendocrine tumor subject continued to receive treatment and showed Stable Disease in imaging evaluation, providing an encouraging preliminary reference for the subsequent clinical development strategy of LXP108.
Langqi Biomedical stated that LXP108 is an innovative anti-cancer drug candidate that the company is focusing on promoting, and has accumulated a complete foundation of pharmacology, pharmacokinetics, toxicology and formulation development in the past. The company will continue to steadily promote subsequent dose escalation and preliminary efficacy signal evaluation based on clinical data and safety review results, and prudently plan the clinical development direction of Phase II, hoping to gradually increase the product value and future commercialization potential of LXP108.
Summary
2026/05/05 16:25:53 Economic Daily Reporter Ren Junxiang/Taipei Instant Report Langchi Biomedical* (6876) stated on the 5th that the company’s independently developed multi-target kinase inhibitor candidate new drug LXP108 (LXP1788 Injection), the first phase of dose escalation clinical trials for advanced solid tumors is progressing smoothly, and the fourth dose group of 0.72 has been completed mg/kg, once weekly dosing (QW) safety review, and successfully advanced to the next dose group. Langzi Biomedicine said that the current treatment of advanced solid tumors still faces multiple challenges, including high tumor heterogeneity, resistance to single-target drugs, limited back-line treatment options, and the lack of effective treatment options for some patients after existing treatments. LXP108 is designed with multi-target kinase inhibition as the core. It hopes to supplement the limitations of existing single-target treatments in tumor escape and drug resistance control by simultaneously regulating multiple message transmission pathways related to tumor growth, metastasis and drug resistance. This differentiated design gives LXP108 the potential to be applied to a variety of advanced solid tumors and is expected to provide new solutions to highly unmet clinical treatment needs. Up to now, LXP108 has completed evaluation in dose groups of 0.09, 0.18, 0.36 and 0.72 mg/kg, and no dose-limiting toxicity (DLT), serious adverse event (SAE) or suspected unexpected serious adverse drug reaction (SUSAR) has been observed. Among them, the fourth dose group of 0.72 mg/kg has entered the dose range with clinical observation significance. It still maintains good safety and tolerability at this stage, providing positive support for the subsequent advancement of higher dose groups and the evaluation of preliminary efficacy signals. In addition, in the 0.72 mg/kg dose group, one neuroendocrine tumor subject continued to receive treatment and showed Stable Disease in imaging evaluation, providing an encouraging preliminary reference for the subsequent clinical development strategy of LXP108. Langqi Biomedical stated that LXP108 is an innovative anti-cancer drug candidate that the company is focusing on promoting, and has accumulated a complete foundation of pharmacology, pharmacokinetics, toxicology and formulation development in the past. The company will continue to steadily promote subsequent dose escalation and preliminary efficacy signal evaluation based on clinical data and safety review results, and prudently plan the clinical development direction of Phase II, hoping to gradually increase the product value and future commercialization potential of LXP108.